HQIP | June 2018 | National Audit of Breast Cancer in Older Patients: 2018 Annual Report
Health Quality Improvement Programme (HQIP) has produced a report which presents information on the care received by women diagnosed between 1 January 2014 and 31 December 2016 in England and Wales. As well as describing how these patterns of care differ between women in the younger and older age groups, the report also distinguishes between three main groups of breast cancer – women with ductal carcinoma in situ, with early invasive disease , and with advanced disease.
The report is primarily written for clinicians, providers of breast cancer services, commissioners and healthcare regulators. A version for patients and the general public will be available in summer 2018 (Source: HQIP).
Department of Health and Social Care | 2018| Report of the Task and Finish
Working Group on Brain Tumour Research
The conclusions of the Department of Health and Social Care (DHSC) task and finish working group on brain tumour research have been published. The working group comprised clinicians, charities, a patient carer and officials to discuss how to increase the level and impact of research into brain tumours, removing barriers to research and how to generate high-quality research. It is the first time that research funders have joined together to look at how this area can be developed (DHSC).
Following such a prolonged period of under-funding, the Working Group identified the of fundable research applications currently being received as a principal issue,
which occurs for many reasons and needs to be tackled systematically. Therefore, they focused on identifying opportunities for removing barriers and generating additional high quality research applications. (DHSC)
The National Lung Cancer Audit annual report 2016, commissioned by the Healthcare Quality Improvement Partnership (HQIP), shows an encouraging rise in survival as more patients receive life-prolonging treatments.
The report covers patients with lung cancer first diagnosed in 2015. It says there was a 7% increase in the number of people diagnosed with lung cancer surviving for longer than one year – rising from 31% to 38% in the five-year period from 2010 to 2015.
In addition, 60% of lung cancer patients received anti-cancer treatment such as chemotherapy, radiotherapy or surgery, meeting the target set out in the 2015 annual audit report.
This is the 12th report on the clinical component (process of care) of the National Lung Cancer Audit. It publishes national and named team results on the quality of lung cancer care for patients diagnosed between 1 January and 31 December 2015. The key findings include a 7% rise in one-year survivorship since 2010.
90% of men receiving curative treatment for prostate cancer say their care was very good
Prostate cancer is the most frequently diagnosed cancer in men and the third most common cause of cancer-related mortality in the United Kingdom, with about 40,000 new cases each year resulting in 10,000 deaths. The NPCA audit looks at whether NHS services in England and Wales for men diagnosed with prostate cancer meet recommended standards.
This is the third Annual Report from the National Prostate Cancer Audit (NPCA) and presents current data regarding prostate cancer care in England and in Wales. In this report, the NPCA gathered information directly from patients to find out their views of their experience of care and the functional impact of radical treatments on their lives.
A total of £1.27bn (€1.7bn; $1.9bn) has so far been spent on the Cancer Drugs Fund in England, but no data exist to show whether it has been spent wisely, the House of Commons Public Accounts Committee says in a new report.
Despite the Department of Health noting when the fund was set up in 2010 that it was important to collect clinical outcomes from the drugs it pays for, few data exist. The department encouraged NHS trusts to collect data but did not require them to do so. When NHS England took over the fund in April 2014 it made data collection mandatory, but the committee still found gaps for 2014-15, with 93% of records having no summary of outcomes.
The health department and NHS England “have not managed the fund effectively” the report concluded.
On the positive side, the committee found that the gap between the United Kingdom and other advanced economies in the uptake of novel cancer treatments had narrowed. In 2009 use of new cancer drugs in the UK was only 45% of the average figure across 13 other countries. But by 2013 it had reached 92%, and NHS England said that it was likely to have improved still further since then. The committee considered that the fund must have contributed to this improvement, even though it applies only in England and not in the rest of the UK.
A new report from cancer charity Macmillan makes the case for government and the NHS to implement the recommendations laid out in the cancer strategy so that everyone with cancer gets the best possible care and support.